Gatipotuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | tumor specific glycosylation of MUC1 |
| Clinical data | |
| Other names | PankoMab-GEX, anti-TA-MUC1 |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
PankoMab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] PankoMab is being developed by Glycotope GMBH [2] and is currently undergoing a phase II clinical trial for ovarian cancer [3]
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |